chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site rash
Clinical narrative: Small local rash; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (Small local rash) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 48A21A and 030M20A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included MULTIVITAMIN [VITAMINS NOS] for Vitamin supplementation.   On 25-Feb-2021 at 1:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021 at 2:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 26-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE RASH (Small local rash). On 07-Mar-2021, VACCINATION SITE RASH (Small local rash) had resolved.            Action taken with mRNA-1273 in response to the events was not applicable.  No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.    This case was linked to MOD-2021-117037, MOD-2021-036644 (Patient Link).
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Sore left injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore left injection site) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient experienced VACCINATION SITE PAIN (Sore left injection site). At the time of the report, VACCINATION SITE PAIN (Sore left injection site) outcome was unknown.            Action taken with mRNA-1273 in response to the events was not applicable. No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.    This case was linked to MOD-2021-117044 (Patient Link).
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Malaise, Migraine, Pain in extremity, Pyrexia
Clinical narrative: did not feel well for 10 days; migraine; arm hurting; Chills; Fever; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (did not feel well for 10 days), MIGRAINE (migraine), PAIN IN EXTREMITY (arm hurting), CHILLS (Chills) and PYREXIA (Fever) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MALAISE (did not feel well for 10 days), MIGRAINE (migraine), PAIN IN EXTREMITY (arm hurting), CHILLS (Chills) and PYREXIA (Fever). At the time of the report, MALAISE (did not feel well for 10 days), MIGRAINE (migraine), PAIN IN EXTREMITY (arm hurting), CHILLS (Chills) and PYREXIA (Fever) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-116606 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: Added events, updated event outcome
Sex: U
Vaccine: COVID19
Symptoms: Syringe issue, Underdose
Clinical narrative: Vaccine due needle leakage, patient did not attain the full dose; Vaccine due needle leakage, patient did not attain the full dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (Vaccine due needle leakage, patient did not attain the full dose) and SYRINGE ISSUE (Vaccine due needle leakage, patient did not attain the full dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced UNDERDOSE (Vaccine due needle leakage, patient did not attain the full dose) and SYRINGE ISSUE (Vaccine due needle leakage, patient did not attain the full dose). At the time of the report, UNDERDOSE (Vaccine due needle leakage, patient did not attain the full dose) and SYRINGE ISSUE (Vaccine due needle leakage, patient did not attain the full dose) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Acoustic stimulation tests, Hypoacusis, Tinnitus
Clinical narrative: low grade tinnitus; minimal hearing loss; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (low grade tinnitus) and HYPOACUSIS (minimal hearing loss) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A2A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced TINNITUS (low grade tinnitus) and HYPOACUSIS (minimal hearing loss). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, TINNITUS (low grade tinnitus) had not resolved and HYPOACUSIS (minimal hearing loss) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Mar-2021, Acoustic stimulation tests: abnormal (abnormal) minimal hearing loss.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications included all kinds of supplements   This case was linked to MOD-2021-117061 (Patient Link).
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site swelling
Clinical narrative: swelling at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE SWELLING (swelling at the injection site) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE SWELLING (swelling at the injection site). The patient was treated with DICLOFENAC at an unspecified dose and frequency. At the time of the report, INJECTION SITE SWELLING (swelling at the injection site) had resolved.            Treatment information included Vit B  Action taken with mRNA-1273 in response to the events was not applicable. No concomitant medications information was reported.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-052881 (Patient Link).
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Acoustic stimulation tests, Magnetic resonance imaging head, Tinnitus
Clinical narrative: Ringing in ears worse and louder; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of TINNITUS (Ringing in ears worse and louder) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017b21A and 010A21A) for COVID-19 vaccination.     Concurrent medical conditions included Sulfonamide allergy (sulfa) and Soy allergy. Concomitant products included AMITRIPTYLINE HYDROCHLORIDE (ELAVIL [AMITRIPTYLINE HYDROCHLORIDE]) for Cystitis, ALPRAZOLAM (XANAX) from 2020 to an unknown date for an unknown indication.   On 03-Mar-2021 at 9:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021 at 9:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced TINNITUS (Ringing in ears worse and louder). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, TINNITUS (Ringing in ears worse and louder) had not resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Acoustic stimulation tests: abnormal (abnormal) minimal damage. On an unknown date, Magnetic resonance imaging head: normal (normal) normal.         treatment medication includes steroids.  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was not applicable.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-117049 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: updated patient demographics, added patient medical history, added  lab data, concomitant medication, treatment medication.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Pain in extremity, Vaccination site pain, Vaccination site swelling
Clinical narrative: "numbness"; "hole upper arm from elbow aching"; "bad pain" in arm in injection side; swelling; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA ("numbness"), PAIN IN EXTREMITY ("hole upper arm from elbow aching"), VACCINATION SITE PAIN ("bad pain" in arm in injection side) and VACCINATION SITE SWELLING (swelling) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included VITAMIN D [VITAMIN D NOS] for an unknown indication.   On 10-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-May-2021, the patient experienced HYPOAESTHESIA ("numbness"), PAIN IN EXTREMITY ("hole upper arm from elbow aching"), VACCINATION SITE PAIN ("bad pain" in arm in injection side) and VACCINATION SITE SWELLING (swelling). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and IBUPROFEN at an unspecified dose and frequency. At the time of the report, HYPOAESTHESIA ("numbness"), PAIN IN EXTREMITY ("hole upper arm from elbow aching"), VACCINATION SITE PAIN ("bad pain" in arm in injection side) and VACCINATION SITE SWELLING (swelling) outcome was unknown.            patient used Tylenol at morning 11am and ibuprofen at 3pm.  Action taken with mRNA-1273 in response to the events was not applicable.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: had a 16 year old patient who received the first dose of the Moderna covid-19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (had a 16 year old patient who received the first dose of the Moderna covid-19 vaccine) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (had a 16 year old patient who received the first dose of the Moderna covid-19 vaccine). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (had a 16 year old patient who received the first dose of the Moderna covid-19 vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported.  No treatment medications were provided
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: pharmacist asked what to do with a patient who passed the 42 day mark to get the second dose of the Moderna vaccine, should the patient repeat the dose or not; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (pharmacist asked what to do with a patient who passed the 42 day mark to get the second dose of the Moderna vaccine, should the patient repeat the dose or not) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (pharmacist asked what to do with a patient who passed the 42 day mark to get the second dose of the Moderna vaccine, should the patient repeat the dose or not). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (pharmacist asked what to do with a patient who passed the 42 day mark to get the second dose of the Moderna vaccine, should the patient repeat the dose or not) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Age: 95.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Whole body itching; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Whole body itching) in a 95-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRURITUS (Whole body itching). At the time of the report, PRURITUS (Whole body itching) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Reporter did not allow further contact
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Chills, Cough, Feeding disorder
Clinical narrative: Coughing; Not able to eat; Severe pain in hip, joints, and back; Vomiting; Headache; Chills; Severe pain in hip, joints, and back; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of COUGH (Coughing), FEEDING DISORDER (Not able to eat), BACK PAIN (Severe pain in hip, joints, and back), VOMITING (Vomiting) and HEADACHE (Headache) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016N20A and 041L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Blood pressure (Very high after vaccine- increased medication.) since 2000, Asthma (Increased coughing- steroid treatment) since 2007, Penicillin allergy, Drug allergy (Demarol), Drug allergy (Keflex.), Drug allergy (Diltiazem), Drug allergy (Rymed) and Drug allergy (Clonidine). Concomitant products included PANTOPRAZOLE for Acid reflux (esophageal), FLUTICASONE FUROATE, VILANTEROL TRIFENATATE (BREO ELLIPTA) and SALBUTAMOL SULFATE (PROAIR [SALBUTAMOL SULFATE]) for Asthma, CARVEDILOL and HYDROCHLOROTHIAZIDE for Blood pressure, CARBIDOPA for Restless legs, CALCIUM for an unknown indication.   On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021 at 3:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Feb-2021, the patient experienced ARTHRALGIA (Severe pain in hip, joints, and back). On an unknown date, the patient experienced COUGH (Coughing), FEEDING DISORDER (Not able to eat), BACK PAIN (Severe pain in hip, joints, and back), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills). At the time of the report, COUGH (Coughing), FEEDING DISORDER (Not able to eat), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills) outcome was unknown and BACK PAIN (Severe pain in hip, joints, and back) and ARTHRALGIA (Severe pain in hip, joints, and back) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Mar-2021, SARS-CoV-2 test: negative (Negative) negative.         Action taken with mRNA-1273 in response to the events was not applicable.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to US-MODERNATX, INC.-MOD-2021-032910 (Patient Link).
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, SARS-CoV-2 test, Vomiting
Clinical narrative: Coughing; Not able to eat; Severe pain in hip, joints, and back; Vomiting; Headache; Chills; Severe pain in hip, joints, and back; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of COUGH (Coughing), FEEDING DISORDER (Not able to eat), BACK PAIN (Severe pain in hip, joints, and back), VOMITING (Vomiting) and HEADACHE (Headache) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016N20A and 041L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Blood pressure (Very high after vaccine- increased medication.) since 2000, Asthma (Increased coughing- steroid treatment) since 2007, Penicillin allergy, Drug allergy (Demarol), Drug allergy (Keflex.), Drug allergy (Diltiazem), Drug allergy (Rymed) and Drug allergy (Clonidine). Concomitant products included PANTOPRAZOLE for Acid reflux (esophageal), FLUTICASONE FUROATE, VILANTEROL TRIFENATATE (BREO ELLIPTA) and SALBUTAMOL SULFATE (PROAIR [SALBUTAMOL SULFATE]) for Asthma, CARVEDILOL and HYDROCHLOROTHIAZIDE for Blood pressure, CARBIDOPA for Restless legs, CALCIUM for an unknown indication.   On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021 at 3:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Feb-2021, the patient experienced ARTHRALGIA (Severe pain in hip, joints, and back). On an unknown date, the patient experienced COUGH (Coughing), FEEDING DISORDER (Not able to eat), BACK PAIN (Severe pain in hip, joints, and back), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills). At the time of the report, COUGH (Coughing), FEEDING DISORDER (Not able to eat), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills) outcome was unknown and BACK PAIN (Severe pain in hip, joints, and back) and ARTHRALGIA (Severe pain in hip, joints, and back) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Mar-2021, SARS-CoV-2 test: negative (Negative) negative.         Action taken with mRNA-1273 in response to the events was not applicable.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to US-MODERNATX, INC.-MOD-2021-032910 (Patient Link).
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, SARS-CoV-2 test
Clinical narrative: Got sick in the stomach after receiving the first; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL DISCOMFORT (Got sick in the stomach after receiving the first) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in December 2020. Concurrent medical conditions included Type 2 diabetes mellitus. Concomitant products included INSULIN DETEMIR (LEVEMIR) and INSULIN for Type 2 diabetes mellitus.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ABDOMINAL DISCOMFORT (Got sick in the stomach after receiving the first). At the time of the report, ABDOMINAL DISCOMFORT (Got sick in the stomach after receiving the first) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2020, SARS-CoV-2 test: positive (Positive) Positive.     mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Treatment information was not provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-117145 (Patient Link).
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Diplopia, Eye infection, Herpes zoster, Ocular hyperaemia
Clinical narrative: shingles/diagnosed as having the shingles; Developed double vision; eye infection; redness; This spontaneous case was reported by a nurse and describes the occurrence of HERPES ZOSTER (shingles/diagnosed as having the shingles), DIPLOPIA (Developed double vision), EYE INFECTION (eye infection) and OCULAR HYPERAEMIA (redness) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included LISINOPRIL, METOPROLOL, ATORVASTATIN and ACETYLSALICYLIC ACID (ASPIRINE) for an unknown indication.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced HERPES ZOSTER (shingles/diagnosed as having the shingles). In February 2021, the patient experienced DIPLOPIA (Developed double vision), EYE INFECTION (eye infection) and OCULAR HYPERAEMIA (redness). The patient was treated with VALACYCLOVIR [VALACICLOVIR] for Shingles, at an unspecified dose and frequency; TOBRAMYCIN for Eye infection, at an unspecified dose and frequency and DEXAMETHASONE for Eye infection, at an unspecified dose and frequency. At the time of the report, HERPES ZOSTER (shingles/diagnosed as having the shingles), DIPLOPIA (Developed double vision), EYE INFECTION (eye infection) and OCULAR HYPERAEMIA (redness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient experienced symptoms which started 02feb2021 about two weeks later, of a rash on her forehead and faced and was diagnosed with the hives initially but within 24 hours caller was diagnosed as having the shingles by her healthcare provider.  valacyclovir was taken for 2 weeks and the medication "didn't helped the shingles got better".  Caller developed double vision, with an eyed infection and redness and was treated with valacyclovir for 10 more days by her healthcare provider.  Caller was started on tobramycin and dexamethasone ophthalmic suspension for her eyes.   Most recent FOLLOW-UP information incorporated above includes: On 11-May-2021: Significant follow up information included reporter details, patient demographic, suspect details, concomitant medication, treatment medication added.
Sex: U
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: soreness in my left arm for about 2-3 days; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (soreness in my left arm for about 2-3 days) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (soreness in my left arm for about 2-3 days). At the time of the report, PAIN IN EXTREMITY (soreness in my left arm for about 2-3 days) had resolved.            Action taken with mRNA-1273 in response to the events was not applicable.  No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to US-MODERNATX, INC.-MOD-2021-117219 (Patient Link).
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: diagnosed with COVID-19; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (diagnosed with COVID-19) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced COVID-19 (diagnosed with COVID-19). At the time of the report, COVID-19 (diagnosed with COVID-19) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Apr-2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Sex: U
Vaccine: COVID19
Symptoms: Somnolence
Clinical narrative: severe drowsiness; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (severe drowsiness) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE (severe drowsiness). At the time of the report, SOMNOLENCE (severe drowsiness) outcome was unknown.            Action taken with mRNA-1273 in response to the events was not applicable.  No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-117202, INC.-MOD-2021-117202 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: same symptoms; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (same symptoms) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (same symptoms). At the time of the report, VACCINATION COMPLICATION (same symptoms) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments   This case was linked to US-MODERNATX, INC.-MOD-2021-054380 (Patient Link).
Age: 20.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Fatigue, Vaccination site pain
Clinical narrative: fatigue; VACCINATION SITE PAIN; This spontaneous case was reported by an other and describes the occurrence of VACCINATION SITE PAIN (VACCINATION SITE PAIN) and FATIGUE (fatigue) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for an unknown indication.    Concurrent medical conditions included Drug allergy (sulfa antibiotics allergy), Latex allergy and Allergy. Concomitant products included GABAPENTIN, NORETHINDRONE ACETATE, IRON, LEVONORGESTREL, ESCITALOPRAM OXALATE (LEXAPRO), LEFLUNOMIDE and IBUPROFEN for an unknown indication.   In March 2021, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On 09-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In March 2021, the patient experienced VACCINATION SITE PAIN (VACCINATION SITE PAIN). In April 2021, the patient experienced FATIGUE (fatigue). At the time of the report, VACCINATION SITE PAIN (VACCINATION SITE PAIN) and FATIGUE (fatigue) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable
Age: 49.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Fatigue, Musculoskeletal stiffness, Pain, Somnolence
Clinical narrative: sleepy; limbs stiffness; ache; tiredness; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of SOMNOLENCE (sleepy), MUSCULOSKELETAL STIFFNESS (limbs stiffness), PAIN (ache) and FATIGUE (tiredness) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) dosage form. On an unknown date, the patient experienced SOMNOLENCE (sleepy), MUSCULOSKELETAL STIFFNESS (limbs stiffness), PAIN (ache) and FATIGUE (tiredness). At the time of the report, SOMNOLENCE (sleepy), MUSCULOSKELETAL STIFFNESS (limbs stiffness), PAIN (ache) and FATIGUE (tiredness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Reporter did not allow further contact
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness
Clinical narrative: Stiffness; This spontaneous case was reported by a physician and describes the occurrence of MUSCULOSKELETAL STIFFNESS (Stiffness) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis (Moderate to severe chronic).   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced MUSCULOSKELETAL STIFFNESS (Stiffness). At the time of the report, MUSCULOSKELETAL STIFFNESS (Stiffness) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. Treatment information was not provided. It was not known whether the patient was enrolled in a Covid-19 vaccine trial. The reporter's causality for co-suspect drug, adalimumab, was not provided.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Cough
Clinical narrative: Non productive cough; This spontaneous case was reported by an other health care professional and describes the occurrence of COUGH (Non productive cough) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COUGH (Non productive cough). At the time of the report, COUGH (Non productive cough) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was withdrawn on an unknown date.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications information was reported. No treatment medications were provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure increased, Blood pressure measurement, Nausea
Clinical narrative: Rise in blood pressure 150/119; nauseous; This spontaneous case was reported by a physician and describes the occurrence of BLOOD PRESSURE INCREASED (Rise in blood pressure 150/119) and NAUSEA (nauseous) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No Medical History information was reported.   On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) dosage form. On 13-Apr-2021, the patient experienced BLOOD PRESSURE INCREASED (Rise in blood pressure 150/119) and NAUSEA (nauseous). At the time of the report, BLOOD PRESSURE INCREASED (Rise in blood pressure 150/119) and NAUSEA (nauseous) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-Apr-2021, Blood pressure measurement: 150/119 (High) 150/119.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment medication was reported.
Age: 92.0
Sex: U
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a 92-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunization.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm). At the time of the report, PAIN IN EXTREMITY (sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.    This case was linked to mod-2021-117522 (Patient Link).
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Pyrexia
Clinical narrative: generalized weakness; Fever; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (generalized weakness) and PYREXIA (Fever) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included ESCITALOPRAM OXALATE (LEXAPRO) for an unknown indication.    In March 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, the patient experienced ASTHENIA (generalized weakness) and PYREXIA (Fever). At the time of the report, ASTHENIA (generalized weakness) and PYREXIA (Fever) had resolved.            Treatment drugs were not provided
Age: 92.0
Sex: U
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Sore arm) in a 92-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm). At the time of the report, PAIN IN EXTREMITY (Sore arm) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable.  No concomitant medications were reported.  No treatment medications provided by the reporter.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Heart rate increased
Clinical narrative: Dizziness; Light headed; Increased heart rate; This spontaneous case was reported by a nurse and describes the occurrence of DIZZINESS (Dizziness), DIZZINESS (Light headed) and HEART RATE INCREASED (Increased heart rate) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M20A and 025L20A) for COVID-19 vaccination.     Previously administered products included for an unreported indication: FLUVIRINE (0.5ml) on 04-Oct-2012, FLUVIRINE (0.5ml) since 03-Oct-2013, TDAP (0.5ml, intramuscular) on 13-Nov-2014, AFLURIA (Flu- 0.5ml, intramuscular) on 13-Nov-2014, HEPATITIS B VACCIN (20mcg, intramuscular) on 01-Dec-2014, HEPATITIS B VACCIN (20mcg, intramuscular) on 09-Jan-2015, FLU VACCINE VII on 12-Sep-2016, FLULAVAL (0.5ml) on 12-Sep-2016, AFLURIA (Flu) on 03-Sep-2018 and FLUCELVAX (0.5ml) on 16-Sep-2020. Concurrent medical conditions included Seasonal allergy, Dust allergy, Mite allergy, Cockroach allergy and Allergy to plants (Sycamore). Concomitant products included ASCORBIC ACID (VITAMIN C ACID) for Immune enhancement therapy, MULTIVITAMIN [VITAMINS NOS] for Supplementation therapy.   On 27-Dec-2020 at 8:23 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 ml. On 01-Feb-2021 at 1:20 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 ml. On 01-Feb-2021, the patient experienced DIZZINESS (Dizziness), DIZZINESS (Light headed) and HEART RATE INCREASED (Increased heart rate). At the time of the report, DIZZINESS (Dizziness), DIZZINESS (Light headed) and HEART RATE INCREASED (Increased heart rate) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment of the events included, diphenhydramine , cetirizine for 2 weeks. Patient was informed to take paracetamol and ibuprofen id patient was feeling unwell   Most recent FOLLOW-UP information incorporated above includes: On 29-Mar-2021: NNI follow up received.  Pt stated has already submitted the forms
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: soreness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (soreness at injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 31-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (soreness at injection site). At the time of the report, VACCINATION SITE PAIN (soreness at injection site) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable  No relevant concomitant medications were reported  No treatment information was provided.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site hypersensitivity
Clinical narrative: Delayed injection site (hypersensitivity) reaction; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE HYPERSENSITIVITY (Delayed injection site (hypersensitivity) reaction) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036A21A and 039K20A) for COVID-19 vaccination.     The patient's past medical history included Irritable bowel syndrome (post-infectious IBS). Concurrent medical conditions included Penicillin allergy, Primary biliary cholangitis (Chronically elevated liver enzymes) since 06-Jan-2020 and Hypertension since 01-May-2009. Concomitant products included VALSARTAN from 05-May-2009 to an unknown date for Hypertension, AMITRIPTYLINE from 15-Aug-2018 to an unknown date for Irritable bowel syndrome, URSODIOL from 06-Jan-2020 to an unknown date for Primary biliary cholangitis, MINERALS NOS, VITAMINS NOS (CENTRUM A TO ZINC) for Supplementation therapy.   On 07-Feb-2021 at 4:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021 at 4:30 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 13-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE HYPERSENSITIVITY (Delayed injection site (hypersensitivity) reaction). On 14-Mar-2021, VACCINATION SITE HYPERSENSITIVITY (Delayed injection site (hypersensitivity) reaction) had resolved.            As per the reporter, the reaction did not require any treatment.      Most recent FOLLOW-UP information incorporated above includes: On 11-May-2021: No new information provided.
Sex: U
Vaccine: COVID19
Symptoms: Feeling abnormal
Clinical narrative: I was so miserable; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (I was so miserable) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (I was so miserable). At the time of the report, FEELING ABNORMAL (I was so miserable) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications provided. No treatment details provided for this event.
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Feeling abnormal, Headache, Vaccination site pain, Vaccination site warmth
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (vaccination site warmth), FEELING ABNORMAL (Foggy feeling in head), ASTHENIA (energy decreased), VACCINATION SITE PAIN (vaccination site pain) and HEADACHE (headache) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.). Concomitant products included RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced VACCINATION SITE WARMTH (vaccination site warmth) and VACCINATION SITE PAIN (vaccination site pain). On an unknown date, the patient experienced FEELING ABNORMAL (Foggy feeling in head), ASTHENIA (energy decreased) and HEADACHE (headache). At the time of the report, VACCINATION SITE WARMTH (vaccination site warmth), FEELING ABNORMAL (Foggy feeling in head), ASTHENIA (energy decreased), VACCINATION SITE PAIN (vaccination site pain) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information not reported.
Sex: U
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive
Clinical narrative: Tested positive; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Tested positive) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Mar-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Tested positive). At the time of the report, SARS-COV-2 TEST POSITIVE (Tested positive) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-Mar-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (COVID 19 Vaccine Moderna) (Unknown), the reporter did not provide any causality assessments.  The patient reported tested positive, after patient's husband was admitted to the hospital with COVID-19 symptoms and never got sick. No concomitant medications were reported.  No treatment information for the event was reported.